Literature DB >> 19149761

TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges.

Anita C Bellail1, Ling Qi, Patrick Mulligan, Vaninder Chhabra, Chunhai Hao.   

Abstract

Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is normally expressed in the human immune system and plays a critical role in antitumor immunity. TRAIL interacts with the death receptors, DR4 and DR5, and activates intracellular apoptotic pathway in cancer cells. This discovery has resulted in a rapid development of cancer therapeutic agents that can activate this apoptotic pathway. These therapeutic agents include recombinant human TRAIL (rhTRAIL) and its agonistic monoclonal antibody (MAb) against DR4 and DR5. Phase I trials have established the safety and tolerability of these TRAIL agonists in patients. Phase II trials are currently evaluating the therapeutic efficacy of TRAIL agonists as single agents or in combination with established cancer therapeutics. This review outlines the advances and the challenges in the development of these TRAIL agonists as effective clinical cancer therapeutics.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19149761     DOI： 10.2174/157488709787047530

Source DB:  PubMed          Journal:  Rev Recent Clin Trials        ISSN： 1574-8871


  78 in total

1.  Death receptor 5 and neuroproliferation.

Authors:  Yanli Niu; Yongqiang Li; Jianfeng Zang; Hongen Huang; Jiexin Deng; Zhanjun Cui; Dongming Yu; Jinbo Deng
Journal:  Cell Mol Neurobiol       Date:  2011-09-22       Impact factor: 5.046

2.  2A peptide-based, lentivirus-mediated anti-death receptor 5 chimeric antibody expression prevents tumor growth in nude mice.

Authors:  Meng Li; Yaomin Wu; Yuhe Qiu; Zhenyu Yao; Shilian Liu; Yanxin Liu; Juan Shi; Dexian Zheng
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

Review 3.  Therapeutic proteins.

Authors:  Dimiter S Dimitrov
Journal:  Methods Mol Biol       Date:  2012

4.  Therapeutic antibodies, vaccines and antibodyomes.

Authors:  Dimiter S Dimitrov
Journal:  MAbs       Date:  2010-05-14       Impact factor: 5.857

5.  Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax.

Authors:  Subash C Gupta; Simone Reuter; Kanokkarn Phromnoi; Byoungduck Park; Padmanabhan S Hema; Mangalam Nair; Bharat B Aggarwal
Journal:  J Biol Chem       Date:  2010-11-15       Impact factor: 5.157

6.  Treatment of arthritis by macrophage depletion and immunomodulation: testing an apoptosis-mediated therapy in a humanized death receptor mouse model.

Authors:  Jun Li; Hui-Chen Hsu; PingAr Yang; Qi Wu; Hao Li; Laura E Edgington; Matthew Bogyo; Robert P Kimberly; John D Mountz
Journal:  Arthritis Rheum       Date:  2011-10-13

7.  Results on efficacy and safety of cancer treatment with or without tumor necrosis factor-related apoptosis-inducing ligand-related agents: A meta-analysis.

Authors:  Shaoxing Sun; Zonghuan Li; Li Sun; Chunxu Yang; Zijie Mei; Wen Ouyang; Bo Yang; Conghua Xie
Journal:  Mol Clin Oncol       Date:  2014-02-18

Review 8.  Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand.

Authors:  Nor Saadah M Azahri; Mary M Kavurma
Journal:  Cell Mol Life Sci       Date:  2013-01-18       Impact factor: 9.261

9.  Monocyte chemotactic protein-induced protein-1 enhances DR5 degradation and negatively regulates DR5 activation-induced apoptosis through its deubiquitinase function.

Authors:  You-Take Oh; Guoqing Qian; Jiusheng Deng; Shi-Yong Sun
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

10.  Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma.

Authors:  Yulyana Yulyana; Berwini B Endaya; Wai H Ng; Chang M Guo; Kam M Hui; Paula Y P Lam; Ivy A W Ho
Journal:  Stem Cells Dev       Date:  2013-03-26       Impact factor: 3.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.